(Q43284690)

English

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

scientific article published on 26 August 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

Carol Aghajanian

1

object named as

Carol Aghajanian

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

author name string

John A Blessing

2

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Kathleen M Darcy

3

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Gary Reid

4

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Koen DeGeest

5

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Stephen C Rubin

6

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Robert S Mannel

7

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Jacob Rotmensch

8

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Russell J Schilder

9

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

William Riordan

10

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Gynecologic Oncology Group

11

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

language of work or name

0 references

publication date

26 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

115

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

215-220

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

New insights into proteasome function: from archaebacteria to drug development

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

An essential role for NF-kappaB in preventing TNF-alpha-induced cell death

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Suppression of TNF-alpha-induced apoptosis by NF-kappaB

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Optimal flexible designs in phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

The proteasome, a novel protease regulated by multiple mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

The development of proteasome inhibitors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

The proteasome: structure, function, and role in the cell

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Development of the proteasome inhibitor Velcade (Bortezomib).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.023

7 January 2021

Identifiers

10.1016/J.YGYNO.2009.07.023

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43284690&oldid=2046271969"